M. van Kooten Losio

United in Fight against prOstate cancer (UFO) registry: first results from a large, multi‐centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia

Choung-Soo Kim, Y. Pu, C. Ohyama, 2019, BJU international.

Prostate cancer in Asia: design of a patient registry to inform real-world treatments, outcomes, and quality of life

Y. Pu, D. Ye, J. Lee, 2018, Prostate international.

Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study

H. Prince, Je-Jung Lee, J. Hou, 2019, Leukemia & lymphoma.

LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)

M. Burotto, R. Motzer, T. Powles, 2022, Annals of Oncology.

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.

M. Burotto, R. Motzer, T. Powles, 2023, The New England journal of medicine.

Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk.

R. Motzer, T. Powles, T. Choueiri, 2023, Journal of Clinical Oncology.